Development of new chemical drugs is a very difficult and complicated process, involving basic research and confirmation of therapeutic targets, the establishment of biological models and methodologies for in vitro and in vivo screening of lead compounds, the confirmation of the relationship between pharmacokinetic characteristics and targets, the assessment of possible differences between the preclinical safety evaluation and the human body environment, the assessment of whether animal pathological models reflect the etiology of human diseases, and the entire drug development process is extremely long and risky. Most of the lead compounds are eliminated at later stages of development because their efficacy is not ideal or their toxic and adverse effects are too grave or there is no obvious advantage or improvement over those drugs on the market. Here come the questions: How to establish a rapid and effective comprehensive early evaluation system to detect and predict the potential safety and possible clinical efficacy of lead compounds with biological activity? How to provide scientific evidence to help new drug research and development scientists and managers decide what lead compounds should enter the preclinical and subsequent clinical trial stages to minimize development risks? These questions pose major challenges in international new drug research and development.

The company took the lead in the world in constructing the core technology system of integrated drug discovery and early evaluation platform based on chemical genomics. Chemical genomics technology uses a large number of known gene expression data and their functional significance analysis to evaluate and predict the possible molecular pharmacology and toxicology of new compounds through the parallel study of the correlation between the effects of various known compounds (good drugs or failed drugs) and any new compounds on whole gene expression, continuously optimizing the structure of candidate compounds. In this way, the lead compounds with the best comprehensive evaluation results will be discovered and enter the next stage of development, thus reducing the risk of new drug development, which is in consistent with the Critical Path Initiative advocated by the FDA to promote the success rate of innovative drug development.

With the technology development of the field, the company has deeply integrated the new technology of AI-assisted design based on the self-developed drug discovery platform based on chemical genomics, forming a one-stop AI + drug development platform. The company has introduced AI technology platforms, such as the Huawei Cloud EIHealth based on the Pangu Drug Molecule Model and the Hermite® Computational Drug Design Platform of DP Technology, into the integrated drug discovery and early evaluation platform based on chemical genomics, and used artificial intelligence, physical modeling, and high-performance computing to support the early research and development projects of the company.

The core technology and capabilities of the company are the scientific and effective development of innovative mechanism drugs that have clinical differentiation and meet clinical needs, with the support of the molecular discovery and early evaluation based on the chemical genomics technology platform integrated with AI-assisted design and the comprehensive strategy of clinical development of new drugs. The advantages of the core technology and capabilities are reflected in the ability to comprehensively evaluate the efficacy, differentiation, and potential toxicity of new drug candidate compounds earlier, effectively reducing the risk of late-stage development; in the subsequent clinical development stage, the clinical development strategy of new drugs is determined according to the scientific principles and mechanism of action of drugs, the differentiated selection of indications in the therapeutic field and product registration paths, and comprehensive risk control measures. These are well-established approaches that address the core issues facing drug development organizations and have demonstrated their ability to increase the success rate of research and development of innovative drugs.